Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. - Wikidata - awgldk - TriplyDB

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

http://www.wikidata.org/entity/Q35194644

about

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.3D tissue-engineered model of Ewing's sarcoma Acquired resistance to drugs targeting receptor tyrosine kinases Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?Targeted therapy for soft tissue sarcomas in adolescents and young adults.Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.Paediatric and adult malignant glioma: close relatives or distant cousins?Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology.Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency.IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.A simulation-based sample size calculation method for pre-clinical tumor xenograft experiments.Newer medical therapies for metastatic soft tissue sarcoma.Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization.Targeting death receptors: is this trail still hot?Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer.Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine.Acquired Resistance to Drugs Targeting Tyrosine Kinases.

P2860

Q28550980-7193C0AF-9B0B-4C56-AB92-D97991AE4676 Q33406371-0FECEA33-1814-4742-94CC-23D8C336FD59 Q33419115-7F53DADA-1407-4BBC-9801-AC75775F64E3 Q34518277-CFCF5057-7EF8-4952-AC35-13AC43F35032 Q35428655-0CCF05E4-4A42-4BFA-9354-3835D4295409 Q35823437-F9887FC6-59CE-43D6-A1FC-99294A8A39D1 Q35850208-20482174-CF10-4E66-BF96-BEBC998BF0AC Q35880614-C0BC25F4-BAD3-47F5-A404-A186C551441C Q36204986-94C96E0D-19B6-43EC-8D27-C994AE01CD8F Q36617604-7C5D501A-E2A0-4EFB-BF7D-D33AC1C2D694 Q36888962-786E08EE-216B-4DF8-8739-AF4D910A7F38 Q36910364-266A7E69-4C7E-49E7-A26E-9AA52875EB8B Q37742014-3ED28D68-3A35-4AAF-B277-1435A1D3D477 Q37944599-4481D4CB-3C2E-4C16-BA57-5F6190F43F4B Q38013990-FC5B0544-720E-4902-8C51-E70B653F0C29 Q38039443-1976EE3B-12B3-40A0-9170-78A31BD78A2C Q38083655-CFA789BE-632E-43E7-9125-3DFE0D99FE20 Q38113988-C2063685-1719-4824-A2A7-90433C553C6D Q38120777-F2BB4F7A-4EE0-4DF3-BF9D-4C9E390F0E33 Q38260335-D2183720-5B73-4F80-B971-6A9D85D62D2B Q38748961-0DE5F1C8-9EF4-46E4-A645-1A59DF9396AA Q38847837-E758F4F2-C860-483B-A497-31C665D52C4D Q39012067-F3082316-7B25-48CE-82FE-ECCCEB615A30 Q39215732-B83BBDF7-BFB7-44CA-A072-251424774E2F Q39326887-093079D6-B50D-444F-805F-E494D7BE9C37 Q40033141-28B6E98F-1918-48A1-A470-9283ABF398D5 Q40606069-EFC5A9F9-09C6-44CA-AACC-9924F759A6C4 Q42995400-04697DAE-70A1-41CF-9AA6-32DD5627BA72 Q43144913-992CB9ED-2782-40B9-ACA2-433F9E474778 Q50868047-13436455-9CED-401A-BD7E-DC5EC588DD3C Q53701267-9221E93A-69E7-4A3E-A6C7-B8F464B76E15

P2860

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

http://www.wikidata.org/entity/Q35194644

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Combination testing (Stage 2) ...... c preclinical testing program.

@ast

Combination testing (Stage 2) ...... c preclinical testing program.

@en

type

label

Combination testing (Stage 2) ...... c preclinical testing program.

@ast

Combination testing (Stage 2) ...... c preclinical testing program.

@en

prefLabel

Combination testing (Stage 2) ...... c preclinical testing program.

@ast

Combination testing (Stage 2) ...... c preclinical testing program.

@en

P1433

Q35194644-5EC449A6-9EA6-4E23-A81D-41EEE0834E87

P1476

Q35194644-8DFC45E7-F2AD-4AD2-AC2A-09927A8DC8DD

P2093

Q35194644-043E8853-7F93-4624-9BBE-7A21C5DB26D2

Q35194644-20A05DC1-5F46-42A2-94C1-792485C424DD

Q35194644-22E730F7-0C3D-4938-9DF4-2536A069C135

Q35194644-612A0271-3870-4A93-A615-4A0DE1087B1C

Q35194644-8D16ADAC-CE4B-4934-80A7-114D3CAD055C

Q35194644-A922D596-4FDD-4F00-9841-3B78CBE9828C

Q35194644-BA3A5040-036E-49D3-B7D8-2467921CCE1F

Q35194644-BCCA947F-DC62-4262-99F7-907CCBC844D2

P2860

Q35194644-0180BA82-8AF3-4DB5-A31F-7F1681238E02

Q35194644-031679FA-F018-42BC-93AA-F073685F495D

Q35194644-0C47653C-2850-4B95-A9D3-3C14EAA0AD36

Q35194644-16A97113-E095-4F38-B181-B88C4C3FB28B

Q35194644-1715E4C4-8A43-4D2F-A70B-3A311163E6F4

Q35194644-1954C9D9-C70E-453D-A0CE-84103D1985BF

Q35194644-1D953F03-6714-48A2-98DC-790EC4D40A53

Q35194644-342FCAD6-75DE-43A4-9B59-FCC3C69F8E1E

Q35194644-3986F10A-1EFB-46A3-9D5B-36459F2D8213

Q35194644-39E60B86-2EBC-47D5-BCAB-28820682F074

P304

Q35194644-34FB2ED7-8E65-40DA-AC02-8508F0C526EE

P31

Q35194644-18DAA2CB-E7E3-410B-B15C-EDD32F575E9C

P356

Q35194644-BACF7986-6CDA-41CC-BAD8-63DF9D43E527

P433

Q35194644-F55F6B77-A485-46EC-97F8-BC1879C1F541

P478

Q35194644-8D1CA851-B372-4206-B858-276E93DE398C

P50

Q35194644-CC57083F-C7F3-45F5-882C-EA7F84B5303F

P577

Q35194644-94998A7D-7A3D-4AF7-BB8E-1A318F0D0A3B

P5875

Q35194644-47E801BF-D9BF-4AA8-859E-F469D080F237

P698

Q35194644-13493560-9D10-480A-9234-51A7B039E1AF

P932

Q35194644-61B67594-DE46-4E88-83C4-2DCB321ED0ED

P356

P1433

Pediatric Blood & Cancer

P1476

Combination testing (Stage 2) ...... ic preclinical testing program

@en

P2093

Amy W Wozniak

http://www.w3.org/2001/XMLSchema#string

Christopher L Morton

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Jianrong Wu

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Malcolm A Smith

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Stephen T Keir

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.

Insulin-like growth factor II-mediated proliferation of human neuroblastoma.

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

Insulin-like growth factor II in the pathogenesis of human neuroblastoma.

Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II.

P304

729-735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.23157

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Richard G Gorlick

P577

2011-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51182195

http://www.w3.org/2001/XMLSchema#string

P698

21630428

http://www.w3.org/2001/XMLSchema#string

P932

3166415

http://www.w3.org/2001/XMLSchema#string